Last reviewed 2026-05-19 · How we verify

beta-glucan MM-10-001

City of Hope Medical Center · Phase 1 active Biologic ✓ Verified May 2026

beta-glucan MM-10-001 is a Biologic drug developed by City of Hope Medical Center. It is currently in Phase 1 development.

Beta-glucan MM-10-001 is a small molecule intervention that has been studied in a dose escalation safety study in healthy subjects. It has also been investigated in a clinical trial for lung cancer, although the specific role of MM-10-001 in this condition is not specified.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	beta-glucan MM-10-001
Sponsor	City of Hope Medical Center
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

beta-glucan MM-10-001 CI brief — competitive landscape report
beta-glucan MM-10-001 updates RSS · CI watch RSS
City of Hope Medical Center portfolio CI

Frequently asked questions about beta-glucan MM-10-001

What is beta-glucan MM-10-001?

beta-glucan MM-10-001 is a Biologic drug developed by City of Hope Medical Center.

Who makes beta-glucan MM-10-001?

beta-glucan MM-10-001 is developed by City of Hope Medical Center (see full City of Hope Medical Center pipeline at /company/city-of-hope-medical-center).

What development phase is beta-glucan MM-10-001 in?

beta-glucan MM-10-001 is in Phase 1.

Manufacturer: City of Hope Medical Center — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing